Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $34000.0.

  • Lyra Therapeutics' Share-based Compensation fell 9771.97% to $34000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 4069.34%. This contributed to the annual value of $6.7 million for FY2024, which is 1408.19% up from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Share-based Compensation is $34000.0, which was down 9771.97% from $914000.0 recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Share-based Compensation high stood at $2.2 million for Q1 2024, and its period low was $34000.0 during Q3 2025.
  • In the last 5 years, Lyra Therapeutics' Share-based Compensation had a median value of $1.1 million in 2024 and averaged $1.2 million.
  • Per our database at Business Quant, Lyra Therapeutics' Share-based Compensation soared by 13724.42% in 2022 and then plummeted by 9771.97% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Share-based Compensation (Quarter) stood at $782000.0 in 2021, then surged by 124.68% to $1.8 million in 2022, then dropped by 15.65% to $1.5 million in 2023, then surged by 30.84% to $1.9 million in 2024, then plummeted by 98.25% to $34000.0 in 2025.
  • Its Share-based Compensation stands at $34000.0 for Q3 2025, versus $914000.0 for Q2 2025 and $825000.0 for Q1 2025.